Assessing Bio-Rad Laboratories after recent performance Bio-Rad Laboratories (BIO) has attracted attention after a mixed stretch of returns, with the stock roughly flat over the past year but showing ...
In February 2026, Bio-Rad Laboratories reported fourth-quarter 2025 sales of US$693.2 million and net income of US$720 million, marking a return to profitability after a prior-year loss, alongside ...
Fintel reports that on October 1, 2024, Citigroup upgraded their outlook for Bio-Rad Laboratories (NYSE:BIO) from Neutral to Buy. As of September 25, 2024, the average one-year price target for ...
Throughout the last three months, 5 analysts have evaluated Bio-Rad Laboratories (NYSE:BIO), offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...
Ariel Investments, an investment management company, released its “Ariel Appreciation Fund” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, ...
Ariel Investments, an investment management company, released its “Ariel Appreciation Fund” first-quarter 2024 investor letter. A copy of the letter can be downloaded here. The Ariel Appreciation fund ...
Bio-Rad Laboratories, Inc. is an American multinational manufacturer and distributor of life science research and clinical diagnostic products. The company was founded in 1952 in Berkeley, California, ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, and Element Biosciences, Inc., developer of a new DNA sequencing platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results